comscoreHormonal Therapy

Hormonal Therapy

175 Research news
 
 
Article
Having a Partner Seems to Improve Quality of Life in Women With Sexual Side Effects From Breast Cancer Hormonal Therapy

A small study suggests that postmenopausal women with partners may have better quality of life than women without partners when experiencing a number of sexual side effects from hormonal therapy.

 
Article
Kisqali Plus Faslodex Improves Overall Survival in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy.

 
Article
Exercise Reduces Joint Pain Caused by Aromatase Inhibitors

A new study has found that exercise eases joint pain that's a common side effect of aromatase inhibitors.

 
Article
CDK4/6 Inhibitor Plus Aromatase Inhibitor Helps Treat Breast Cancer, No Matter a Woman's Age

An analysis of three studies on different CDK4/6 inhibitors in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer found the treatment combination was effective in both younger and older women.

 
Article
Exercise Eases Memory Problems in Women Treated for Breast Cancer

Women treated for breast cancer who did more moderate-to-vigorous exercise reported fewer memory problems.

 
Article
Women Without Prescription Drug Coverage Less Likely to Start Hormonal Therapy

A study has found that women diagnosed with early-stage, hormone-receptor-positive breast cancer with no prescription drug coverage were less likely to start hormonal therapy than women who had insurance coverage for prescription drugs.

 
Article
Prolia Reduces Recurrence Risk of Hormone-Receptor-Positive Disease in Women Taking Aromatase Inhibitors

A study has found that Prolia improved disease-free survival for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.

 
Article
Telephone Counseling Helps Women Taking Femara Lose Weight

A small study has found that a telephone counseling program helped overweight postmenopausal women diagnosed with early-stage breast cancer who were taking Femara lose weight.

Jul 1, 2014 | Diagnosis and Hormonal Therapy
 
Article
Adding Kisqali Improves Overall Survival in Younger Women With Advanced-Stage Hormone-Receptor-Positive Breast Cancer

Results from the MONALEESA-7 trial show that adding Kisqali to hormonal therapy and ovarian suppression significantly improves overall survival in premenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.

 
Article
Tamoxifen Gel Reduces DCIS Recurrence Risk as Well as Tamoxifen Pills

A small, early study found that a tamoxifen gel applied directly to the breast area of women diagnosed with DCIS stopped cancer cell growth as well as tamoxifen pills and caused fewer side effects.

 
Article
Electroacupuncture Helps Ease Fatigue, Anxiety, and Depression in Women Taking Aromatase Inhibitors

Electroacupuncture – a type of acupuncture where a small electric current passes between pairs of acupuncture needles – has been found to ease fatigue, anxiety, and depression in women diagnosed with early-stage breast cancer who are taking an aromatase inhibitor.

 
Article
Many Younger Women Don't Think Hormonal Therapy Is Necessary

Many young women don't think hormonal therapy is an essential treatment for breast cancer, which may be why they stop the treatment early.

 
Article
Antidepressant Duloxetine Eases Joint Pain Caused by Aromatase Inhibitors

The antidepressant duloxetine can ease joint pain in women diagnosed with early-stage, hormone-receptor-positive breast cancer who are taking an aromatase inhibitor.

 
Article
Adding Afinitor to Faslodex Helps Treat Metastatic Disease That's AI-Resistant

Adding Afinitor to Faslodex offers benefits when treating metastatic, hormone-receptor-positive, HER2-negative breast cancer that has become resistant to aromatase inhibitors.

 
Article
Adding 2 Years of Ovarian Suppression to Tamoxifen Improves Survival in Premenopausal Women With Early-Stage Breast Cancer

Treating premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer with tamoxifen plus 2 years of ovarian suppression after surgery offers better disease-free survival than tamoxifen alone.

Sep 25, 2019 | Diagnosis and Hormonal Therapy
 
Article
Verzenio Plus Faslodex Improves Overall Survival by 9 Months in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Latest results from MONARCH 2 study show adding Verzenio to Faslodex improves overall survival by 9 months for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.

 
Article
Care Improving, but Study Finds Variations in Hormonal Therapy Use After Surgery

A study suggests that appropriate use of adjuvant hormonal therapy has improved since 2004, but still isn't optimal.

Feb 10, 2017 | Diagnosis and Hormonal Therapy
 
Article
Some Older Women With Early-Stage Hormone-Receptor-Positive, Node-Positive Breast Cancer Can Skip Chemotherapy

Postmenopausal women diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive lymph nodes and an Oncotype DX Recurrence Score of 25 or lower being treated with hormonal therapy after surgery can safely skip chemotherapy.

 
Article
Experimental Alpelisib May Help Treat Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer With Specific Mutation

Experimental alpelisib combined with Faslodex improved progression-free survival more than Faslodex alone in people diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

 
Article
Kisqali Can Help Treat Younger Women With Metastatic Hormone-Receptor-Positive Disease

Kisqali along with either an aromatase inhibitor or tamoxifen and medicine to suppress ovarian function offers better progression-free survival than just hormonal therapy and ovarian suppression in premenopausal women with advanced-stage, hormone-receptor-positive, HER2-negative disease.

 
Article
Different Hormonal Therapies Cause Different Side Effects

Hormonal therapy medicines used to reduce the risk of recurrence have different side effects.

 
Article
Postmenopausal Women Benefit From Longer Hormonal Therapy

Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.

 
Article
Tamoxifen Plus Removing Ovaries Improves Survival for Premenopausal Women

Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.

 
Article
Arimidex Doesn't Seem to Cause Thinking or Memory Problems

A small study shows that women who took the aromatase inhibitor Arimidex (chemical name: anastrozole) for 2 years didn't have any more thinking and memory problems than women who took a placebo pill for 2 years.

Showing 24 of 175